Keywords: gsk, halts, serevent, trial, fda, backs, product
GSK halts Serevent trial; FDA backs product
Article | 03 February 2003
GlaxoSmithKline has halted a clinical trial of its big-selling asthmadrug Serevent (salmeterol xinafoate), after an interim analysis of a large ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
